KR100686910B1 - 생체 상태 정보 처리 장치, 생체 상태 정보 처리 방법, 생체 상태 정보 관리 시스템 및 기록 매체 - Google Patents
생체 상태 정보 처리 장치, 생체 상태 정보 처리 방법, 생체 상태 정보 관리 시스템 및 기록 매체 Download PDFInfo
- Publication number
- KR100686910B1 KR100686910B1 KR1020057010476A KR20057010476A KR100686910B1 KR 100686910 B1 KR100686910 B1 KR 100686910B1 KR 1020057010476 A KR1020057010476 A KR 1020057010476A KR 20057010476 A KR20057010476 A KR 20057010476A KR 100686910 B1 KR100686910 B1 KR 100686910B1
- Authority
- KR
- South Korea
- Prior art keywords
- correlation
- blood concentration
- concentration data
- indicator
- metabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000010365 information processing Effects 0.000 title claims abstract description 86
- 238000003672 processing method Methods 0.000 title claims description 32
- 239000002207 metabolite Substances 0.000 claims abstract description 361
- 239000002131 composite material Substances 0.000 claims abstract description 292
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 260
- 238000012545 processing Methods 0.000 claims abstract description 96
- 210000004369 blood Anatomy 0.000 claims description 370
- 239000008280 blood Substances 0.000 claims description 370
- 150000001875 compounds Chemical class 0.000 claims description 229
- 238000000034 method Methods 0.000 claims description 163
- 150000001413 amino acids Chemical class 0.000 claims description 144
- 238000004364 calculation method Methods 0.000 claims description 138
- 238000004458 analytical method Methods 0.000 claims description 95
- 238000005457 optimization Methods 0.000 claims description 64
- 230000002503 metabolic effect Effects 0.000 claims description 58
- 238000003860 storage Methods 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 42
- 238000004088 simulation Methods 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000011218 segmentation Effects 0.000 claims description 5
- 238000005192 partition Methods 0.000 claims description 3
- 238000004891 communication Methods 0.000 abstract description 50
- 238000010586 diagram Methods 0.000 description 102
- 241000700159 Rattus Species 0.000 description 99
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 81
- 206010012601 diabetes mellitus Diseases 0.000 description 59
- 230000008569 process Effects 0.000 description 59
- 230000005540 biological transmission Effects 0.000 description 42
- 208000005176 Hepatitis C Diseases 0.000 description 27
- 230000006870 function Effects 0.000 description 27
- 201000010099 disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 238000005259 measurement Methods 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 230000004060 metabolic process Effects 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 230000000875 corresponding effect Effects 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 13
- 229960003067 cystine Drugs 0.000 description 13
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 10
- 108010050904 Interferons Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 229940079322 interferon Drugs 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 206010019668 Hepatic fibrosis Diseases 0.000 description 8
- 108010000521 Human Growth Hormone Proteins 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 8
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 8
- 229960000698 nateglinide Drugs 0.000 description 8
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 8
- 102000013918 Apolipoproteins E Human genes 0.000 description 7
- 108010025628 Apolipoproteins E Proteins 0.000 description 7
- 102000002265 Human Growth Hormone Human genes 0.000 description 7
- 239000000854 Human Growth Hormone Substances 0.000 description 7
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 241000282887 Suidae Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940026510 theanine Drugs 0.000 description 6
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 5
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 5
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 230000036765 blood level Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 238000005314 correlation function Methods 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 201000010063 epididymitis Diseases 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- -1 lipid peroxide Chemical class 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 4
- 230000002542 deteriorative effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241001500351 Influenzavirus A Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000018823 dietary intake Nutrition 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000037323 metabolic rate Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- YGOTZDUFHLLYJO-UHFFFAOYSA-N 2-azaniumyl-2-hydroxypropanoate Chemical group CC(N)(O)C(O)=O YGOTZDUFHLLYJO-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000021075 protein intake Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101001094649 Homo sapiens Popeye domain-containing protein 3 Proteins 0.000 description 1
- 101000608234 Homo sapiens Pyrin domain-containing protein 5 Proteins 0.000 description 1
- 101000578693 Homo sapiens Target of rapamycin complex subunit LST8 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102100039889 Pyrin domain-containing protein 5 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/20—Heterogeneous data integration
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Bioethics (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002357042 | 2002-12-09 | ||
| JPJP-P-2002-00357042 | 2002-12-09 | ||
| JPJP-P-2003-00205589 | 2003-08-01 | ||
| JP2003205589 | 2003-08-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20050084227A KR20050084227A (ko) | 2005-08-26 |
| KR100686910B1 true KR100686910B1 (ko) | 2007-02-26 |
Family
ID=32510622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057010476A Expired - Lifetime KR100686910B1 (ko) | 2002-12-09 | 2003-12-09 | 생체 상태 정보 처리 장치, 생체 상태 정보 처리 방법, 생체 상태 정보 관리 시스템 및 기록 매체 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8234075B2 (enExample) |
| EP (2) | EP2357581A3 (enExample) |
| JP (3) | JP4581994B2 (enExample) |
| KR (1) | KR100686910B1 (enExample) |
| AU (1) | AU2003289263A1 (enExample) |
| CA (2) | CA2637250A1 (enExample) |
| WO (1) | WO2004052191A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2637250A1 (en) | 2002-12-09 | 2004-06-24 | Ajinomoto Co., Inc. | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
| WO2006098192A1 (ja) * | 2005-03-16 | 2006-09-21 | Ajinomoto Co., Inc. | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラム、評価関数作成装置、評価関数作成方法、評価関数作成プログラムおよび記録媒体 |
| EP1887362A4 (en) * | 2005-05-30 | 2010-01-27 | Ajinomoto Kk | HEPATHOPATHY EVALUATION APPARATUS, HEPATHOPATHY EVALUATION METHOD, HEPATHOPATHY EVALUATION SYSTEM, HEPATHOPATHY EVALUATION PROGRAM, AND RECORDING MEDIUM |
| US20070016389A1 (en) * | 2005-06-24 | 2007-01-18 | Cetin Ozgen | Method and system for accelerating and improving the history matching of a reservoir simulation model |
| EP1865431A1 (en) * | 2006-06-06 | 2007-12-12 | Waters GmbH | System for managing and analyzing metabolic pathway data |
| JP5856364B2 (ja) * | 2006-08-04 | 2016-02-09 | 味の素株式会社 | 抑うつ病の評価方法、抑うつ病評価装置、抑うつ病評価方法、抑うつ病評価システム、抑うつ病評価プログラム、記録媒体および端末装置 |
| WO2008015929A1 (fr) * | 2006-08-04 | 2008-02-07 | Ajinomoto Co., Inc. | procédé d'évaluation de syndrome métabolique, appareil D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, système D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, programme d'évaluation de syndrome métabolique et support d'enregistrement, et proc& |
| JP5470848B2 (ja) * | 2006-08-04 | 2014-04-16 | 味の素株式会社 | 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置 |
| JPWO2008075664A1 (ja) * | 2006-12-21 | 2010-04-15 | 味の素株式会社 | 癌の評価方法、ならびに癌評価装置、癌評価方法、癌評価システム、癌評価プログラムおよび記録媒体 |
| EP2096439A4 (en) * | 2006-12-21 | 2011-01-05 | Ajinomoto Kk | METHOD, APPARATUS, METHOD, SYSTEM AND SOFTWARE FOR EVALUATING COLORECTAL CANCER, AND RECORDING MEDIUM |
| EP2103940A4 (en) | 2006-12-21 | 2013-04-24 | Ajinomoto Kk | METHOD, APPARATUS, METHOD, SYSTEM AND SOFTWARE FOR ASSESSING BREAST CANCER, AND RECORDING MEDIUM |
| WO2008090941A1 (ja) | 2007-01-24 | 2008-07-31 | Ajinomoto Co., Inc. | Ｉｂｄの評価方法、ならびにアミノ酸情報処理装置、アミノ酸情報処理方法、アミノ酸情報処理システム、アミノ酸情報処理プログラムおよび記録媒体 |
| JP5016316B2 (ja) * | 2007-01-31 | 2012-09-05 | メディアクロス株式会社 | メタボリックシンドローム血管評価システム |
| EP2172775A4 (en) * | 2007-06-25 | 2010-12-01 | Ajinomoto Kk | METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION |
| EP2209001A4 (en) * | 2007-10-25 | 2010-10-27 | Ajinomoto Kk | METHOD FOR ASSESSING STROKEN GLUCOSE TOLERANCE |
| WO2009054351A1 (ja) * | 2007-10-25 | 2009-04-30 | Ajinomoto Co., Inc. | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラムおよび記録媒体 |
| KR101361601B1 (ko) * | 2008-03-04 | 2014-02-12 | 아지노모토 가부시키가이샤 | 암종의 평가 방법 |
| JP5754137B2 (ja) | 2008-06-20 | 2015-07-29 | 味の素株式会社 | 前立腺癌の評価方法、前立腺癌評価装置、前立腺癌評価方法、前立腺癌評価プログラム、記録媒体、前立腺癌評価システム、および情報通信端末装置 |
| JP5754136B2 (ja) * | 2008-06-20 | 2015-07-29 | 味の素株式会社 | 女性生殖器癌の評価方法、女性生殖器癌評価装置、女性生殖器癌評価方法、女性生殖器癌評価プログラム、記録媒体、女性生殖器癌評価システム、および情報通信端末装置 |
| WO2010064413A1 (ja) * | 2008-12-01 | 2010-06-10 | 国立大学法人山口大学 | 薬剤の作用・副作用予測システムとそのプログラム |
| JP6260275B2 (ja) | 2011-06-30 | 2018-01-17 | 味の素株式会社 | 脂肪肝の評価方法、脂肪肝評価装置、脂肪肝評価方法、脂肪肝評価プログラム、脂肪肝評価システム、および端末装置 |
| WO2013005790A1 (ja) * | 2011-07-07 | 2013-01-10 | 味の素株式会社 | 生体酸化の評価方法、生体酸化評価装置、生体酸化評価方法、生体酸化評価プログラム、生体酸化評価システム、情報通信端末装置、および生体酸化の予防・改善物質の探索方法 |
| CN103082993B (zh) * | 2011-10-31 | 2016-01-20 | 国民技术股份有限公司 | 人体生物信息检测系统及其检测方法 |
| JP6270257B2 (ja) * | 2012-01-31 | 2018-01-31 | 味の素株式会社 | 取得方法、心血管イベント評価装置、心血管イベント評価プログラム、心血管イベント評価システムおよび端末装置 |
| CN110133298A (zh) * | 2012-03-18 | 2019-08-16 | 株式会社资生堂 | 疾病样品分析装置、分析系统及分析方法 |
| JP6375947B2 (ja) * | 2012-05-11 | 2018-08-22 | 味の素株式会社 | 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置 |
| JP6269502B2 (ja) | 2012-11-27 | 2018-01-31 | 味の素株式会社 | 膵臓癌の評価方法、膵臓癌評価装置、膵臓癌評価方法、膵臓癌評価プログラム、膵臓癌評価システムおよび端末装置 |
| KR102362357B1 (ko) | 2013-04-09 | 2022-02-15 | 아지노모토 가부시키가이샤 | 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치 |
| KR102500075B1 (ko) | 2014-10-08 | 2023-02-16 | 아지노모토 가부시키가이샤 | 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치 |
| JP6886241B2 (ja) * | 2016-01-07 | 2021-06-16 | 味の素株式会社 | 骨格筋面積の評価方法 |
| US10235431B2 (en) | 2016-01-29 | 2019-03-19 | Splunk Inc. | Optimizing index file sizes based on indexed data storage conditions |
| PT3480599T (pt) | 2016-06-30 | 2024-10-18 | Ajinomoto Kk | Método de avaliação da cetose pós-parto |
| WO2018066620A1 (ja) * | 2016-10-04 | 2018-04-12 | 味の素株式会社 | 膵臓癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
| KR102427923B1 (ko) | 2016-10-04 | 2022-08-02 | 아지노모토 가부시키가이샤 | 대장암의 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치 |
| JP7336850B2 (ja) | 2016-12-01 | 2023-09-01 | 味の素株式会社 | 癌モニタリングの方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、および評価システム |
| EP3779453A4 (en) * | 2018-04-10 | 2022-01-05 | Ajinomoto Co., Inc. | METHOD, DEVICE AND PROGRAM FOR EVALUATING THE HEALTH AND / OR GROWTH STATUS OF LIVESTOCK |
| EP3859339A4 (en) | 2018-09-26 | 2022-12-28 | Ajinomoto Co., Inc. | METHOD FOR ASSESSING MILD COGNITIVE IMPAIRMENTS, CALCULATION METHOD, ASSESSMENT DEVICE, CALCULATION DEVICE, ASSESSMENT PROGRAM, CALCULATION PROGRAM, RECORDING MEDIA, ASSESSMENT SYSTEM AND TERMINAL |
| US12163404B2 (en) | 2019-05-24 | 2024-12-10 | National Oilwell Varco, L.P. | Wellsite monitoring system and method |
| US20210225513A1 (en) * | 2020-01-22 | 2021-07-22 | XY.Health Inc. | Method to Create Digital Twins and use the Same for Causal Associations |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61126472A (ja) | 1984-11-24 | 1986-06-13 | Advance Res & Dev Co Ltd | 診断方法 |
| JPH0620459B2 (ja) * | 1987-11-13 | 1994-03-23 | 住友電気工業株式会社 | 肝機能検査装置 |
| KR910002651B1 (ko) | 1987-11-13 | 1991-04-27 | 스미또모 덴끼 고교 가부시끼가이샤 | 간 기능 검사 장치 |
| JP3221610B2 (ja) | 1991-01-18 | 2001-10-22 | エイサ・インコーポレイテツド | 生化学的プロフィールから障害を検出又は類別する方法 |
| WO1996012187A1 (en) | 1994-10-13 | 1996-04-25 | Horus Therapeutics, Inc. | Computer assisted methods for diagnosing diseases |
| DE69610926T2 (de) * | 1995-07-25 | 2001-06-21 | Horus Therapeutics, Inc. | Rechnergestütztes verfahren und anordnung zur diagnose von krankheiten |
| US5687716A (en) | 1995-11-15 | 1997-11-18 | Kaufmann; Peter | Selective differentiating diagnostic process based on broad data bases |
| US6059724A (en) * | 1997-02-14 | 2000-05-09 | Biosignal, Inc. | System for predicting future health |
| US6300136B1 (en) | 1997-09-03 | 2001-10-09 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis and treatment of tumors in humans |
| US20040022827A1 (en) | 1997-09-30 | 2004-02-05 | Chugai Seiyaku Kabusiki Kaisha | Remedy for hepatopathy |
| JPH11190734A (ja) | 1997-12-26 | 1999-07-13 | Wakamoto Pharmaceut Co Ltd | クローン病の検査方法および検査用キット |
| CA2371385A1 (en) | 1999-04-26 | 2000-11-02 | Surromed, Inc. | Phenotype and biological marker identification system |
| EP1228370A2 (en) * | 1999-11-10 | 2002-08-07 | Structural Bioinformatics Inc. | Computationally derived protein structures in pharmacogenomics |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| EP1283024B1 (en) | 2000-04-18 | 2009-03-25 | Yamato Scale Co., Ltd. | Visceral fat meter |
| KR101054732B1 (ko) | 2000-07-18 | 2011-08-05 | 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 | 생물학적 데이터의 숨겨진 패턴에 근거한 생물학적 상태의 식별 방법 |
| JP4545899B2 (ja) | 2000-07-31 | 2010-09-15 | キヤノン株式会社 | 加熱装置および画像形成装置 |
| US6631330B1 (en) | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
| US7062384B2 (en) * | 2000-09-19 | 2006-06-13 | The Regents Of The University Of California | Methods for classifying high-dimensional biological data |
| JP4315603B2 (ja) * | 2001-01-26 | 2009-08-19 | 東京瓦斯株式会社 | 炎症性腸疾患診断剤 |
| JP3933882B2 (ja) | 2001-03-30 | 2007-06-20 | 富士通株式会社 | レーダーチャートを表示させるためのプログラムおよびレーダーチャート表示方法 |
| US20040158581A1 (en) * | 2001-05-21 | 2004-08-12 | Max Kotlyar | Method for determination of co-occurences of attributes |
| JP2003159095A (ja) | 2001-07-12 | 2003-06-03 | Takeda Chem Ind Ltd | 結合分子予測方法およびその利用方法 |
| EP1425695A2 (en) * | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
| CA2399169A1 (en) | 2001-09-07 | 2003-03-07 | Queen's University At Kingston | Diagnostic methods for determining susceptibility to convulsive conditions |
| ES2333181T3 (es) | 2002-03-29 | 2010-02-17 | Asahi Kasei Pharma Corporation | Metodo para la deteccion de una intolerancia ligera a la glucosa o hiposecrecion de insulina. |
| JP2004135546A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | クローン病の疾患マーカー及びその利用 |
| AU2003272234A1 (en) | 2002-10-24 | 2004-05-13 | Warner-Lambert Company, Llc | Integrated spectral data processing, data mining, and modeling system for use in diverse screening and biomarker discovery applications |
| CA2637250A1 (en) | 2002-12-09 | 2004-06-24 | Ajinomoto Co., Inc. | Apparatus and method for processing information concerning biological condition, system, program and recording medium for managing information concerning biological condition |
| JP2004321179A (ja) | 2003-04-07 | 2004-11-18 | Nitto Boseki Co Ltd | 炎症性腸疾患診断用マーカー遺伝子もしくは蛋白質およびそれを利用した炎症性腸疾患診断方法 |
| US7064104B2 (en) | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
| US20060170928A1 (en) | 2003-12-24 | 2006-08-03 | Vadivel Masilamani | Masila's cancer detector based on optical analysis of body fluids |
| JP4200441B2 (ja) | 2003-08-13 | 2008-12-24 | 財団法人柏戸記念財団 | 臨床検査データの可視化表現シートの作成装置 |
| JP2007502992A (ja) * | 2003-08-20 | 2007-02-15 | ビージー メディシン， インコーポレイテッド | 生物システムのプロファイリングのための方法およびシステム |
| US8346482B2 (en) | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
| US7761239B2 (en) | 2003-12-11 | 2010-07-20 | Correlogic Systems, Inc. | Method of diagnosing biological states through the use of a centralized, adaptive model, and remote sample processing |
| US7433853B2 (en) | 2004-07-12 | 2008-10-07 | Cardiac Pacemakers, Inc. | Expert system for patient medical information analysis |
-
2003
- 2003-12-09 CA CA002637250A patent/CA2637250A1/en not_active Abandoned
- 2003-12-09 EP EP11157821A patent/EP2357581A3/en not_active Withdrawn
- 2003-12-09 AU AU2003289263A patent/AU2003289263A1/en not_active Abandoned
- 2003-12-09 EP EP03777384A patent/EP1570779A4/en not_active Withdrawn
- 2003-12-09 KR KR1020057010476A patent/KR100686910B1/ko not_active Expired - Lifetime
- 2003-12-09 JP JP2005502361A patent/JP4581994B2/ja not_active Expired - Lifetime
- 2003-12-09 WO PCT/JP2003/015713 patent/WO2004052191A1/ja not_active Ceased
- 2003-12-09 CA CA002508136A patent/CA2508136A1/en not_active Abandoned
-
2005
- 2005-06-09 US US11/148,352 patent/US8234075B2/en active Active
-
2010
- 2010-07-12 JP JP2010158021A patent/JP5707757B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-30 US US13/483,359 patent/US20120239366A1/en not_active Abandoned
-
2013
- 2013-07-22 JP JP2013152149A patent/JP5971209B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US8234075B2 (en) | 2012-07-31 |
| KR20050084227A (ko) | 2005-08-26 |
| JP2013257333A (ja) | 2013-12-26 |
| JP4581994B2 (ja) | 2010-11-17 |
| US20120239366A1 (en) | 2012-09-20 |
| EP1570779A4 (en) | 2008-03-12 |
| JP5971209B2 (ja) | 2016-08-17 |
| AU2003289263A1 (en) | 2004-06-30 |
| EP1570779A1 (en) | 2005-09-07 |
| JP2010281826A (ja) | 2010-12-16 |
| JPWO2004052191A1 (ja) | 2006-04-06 |
| CA2637250A1 (en) | 2004-06-24 |
| US20050283347A1 (en) | 2005-12-22 |
| JP5707757B2 (ja) | 2015-04-30 |
| WO2004052191A1 (ja) | 2004-06-24 |
| EP2357581A3 (en) | 2012-09-12 |
| CA2508136A1 (en) | 2004-06-24 |
| EP2357581A2 (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100686910B1 (ko) | 생체 상태 정보 처리 장치, 생체 상태 정보 처리 방법, 생체 상태 정보 관리 시스템 및 기록 매체 | |
| Kendale et al. | Supervised machine-learning predictive analytics for prediction of postinduction hypotension | |
| CN105096225B (zh) | 辅助疾病诊疗的分析系统、装置及方法 | |
| Mellon et al. | Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients | |
| European Society of Radiology (ESR) communications@ myesr. Org | ESR position paper on imaging biobanks | |
| CN1751309A (zh) | 结合体外测试数据的医学数据分析方法和设备 | |
| KR20050085778A (ko) | 의료 데이터 처리 방법 및 데이터 처리 시스템 | |
| Comte et al. | Network and systems medicine: Position paper of the european collaboration on science and technology action on open multiscale systems medicine | |
| Sickle Cell Disease Ontology Working Group Adekile Adekunle Anie Kofi A Hamda Cherif Ben Brown Biobele Bukini Daima Campbell Andrew Chaouch Melek Chimusa Emile Chunda-Liyoka Catherine Dennis-Antwi Jemima Derebail Vimal K Flor-Park Miriam Geard Amy Ghedira Kais Haendel Melissa Hanchard Neil A Hotchkiss Jade Jonas Mario Ibrahim Muntaser Ingram Clair Inusa Baba Jimoh Adijat Ozohu Jupp Simon Kamga Karen Kashim Zainab Abimbola Knight-Madden Jennifer Landouré Guida Lopez-Sall Philomene Makani Julie Malasa Leonard Masekoameng Tshepiso Mazandu Gaston Mnika Khuthala Mulder Nicola Munung Nchangwi Syntia Munube Deogratias Mwita Liberata Nembaware Victoria Nnodu Obiageli Ofori-Acquah Solomon Ohene-Frempong Kwaku Osei-Akoto Alex Paintsil Vivian Panji Sumir Rahimy Mohamed Cherif Royal Charmaine Sangeda Raphael Z Tayo Bamidele Tiouiri Ines Tluway Furahini Treadwell Marsha Tshilolo Leon Vasilevsky Nicole Waiswa Kasadhakawo Musa Wonkam Ambroise | The Sickle Cell Disease Ontology: enabling universal sickle cell-based knowledge representation | |
| Lanktree et al. | Phenomics: expanding the role of clinical evaluation in genomic studies | |
| WO2002064826A2 (en) | Network for evaluating data obtained in a biochip measurement device | |
| Granata et al. | Learning from metabolic networks: Current trends and future directions for precision medicine | |
| US8244480B2 (en) | Computer product, analysis support apparatus, and analysis support method | |
| Pan et al. | Machine learning identifies girls with central precocious puberty based on multisource data | |
| Ozkan et al. | QAFI: a novel method for quantitative estimation of missense variant impact using protein-specific predictors and ensemble learning | |
| WO2018126132A1 (en) | Systems and methods for an expert system for precision oncology | |
| CN100502763C (zh) | 生物体状态信息处理装置和其方法、以及生物体状态信息管理系统 | |
| Muñoz-Fuentes et al. | Pleiotropy data resource as a primer for investigating co-morbidities/multi-morbidities and their role in disease | |
| CODATA Task Group on Biological Macromolecules and Colleagues | Quality control in databanks for molecular biology | |
| MXPA06011525A (es) | Sistema y metodos para manejo del tratamiento y datos del paciente. | |
| Faria et al. | The Immunopeptidomics Ontology (ImPO) | |
| Ma | Tumor and pan-tumor diversity and heterogeneity of cancer tissue microbiomes: a medical ecology analysis across 32 cancer types | |
| US20250342972A1 (en) | System and methods for generating clinical predictions based on multimodal medical data | |
| Martín et al. | Integration of omics data for cancer research | |
| Vidović et al. | Comprehensive proteomics metadata and integrative web portals facilitate sharing and integration of LINCS multiomics data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20050609 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050609 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060822 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20061205 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20070220 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20070221 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20100210 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110127 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120130 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20130201 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130201 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20140204 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140204 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20150119 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150119 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160119 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170119 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170119 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20180202 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180202 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20190130 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190130 Start annual number: 13 End annual number: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20200205 Year of fee payment: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200205 Start annual number: 14 End annual number: 14 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210128 Start annual number: 15 End annual number: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220119 Start annual number: 16 End annual number: 16 |
|
| PC1801 | Expiration of term |
Termination date: 20240609 Termination category: Expiration of duration |